Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NVS vs NVO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NVO Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

NVO Overall Winner 6-Pillar Tally: NVS 2 – 4 NVO Matrix Metrics: NVS 3 – 7 NVO

As of Nov 16, 2026, Novo-Nordisk A/S (NVO) is the stronger overall head-to-head candidate over Novartis AG (NVS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas NVO carries 41.8/100 (SELL) at $41.71 (12.2x Forward P/E, 50.8% operating margin).

  • Defensive Composite Rating Caution: Although NVO compares more favorably head-to-head, both NVS (41.5/100 SELL) and NVO (41.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NVS vs NVO
NVS NYSE
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap $302.9B
TTM Revenue $40.5B
Forward P/E 16.2x
Beta / 30D Vol 0.31β · 27% Vol
Unified Composite Score
41.5 / 100 SELL
Tech 29.0 Fund 38.0 Flow 50.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 61
RSI-14: 60.8 · SMA20: $159.19 · SMA50: $149.17
NVO NYSE Head-to-Head Winner
Novo-Nordisk A/S
Pharmaceutical Preparations
$41.71
+0.19% 1D
Market Cap $180.7B
TTM Revenue $51.5B
Forward P/E 12.2x
Beta / 30D Vol 0.50β · 32% Vol
Unified Composite Score
41.8 / 100 SELL
Tech 56.0 Fund 55.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 59
RSI-14: 58.8 · SMA20: $40.14 · SMA50: $39.99

6-Pillar Scorecard Institutional Category Breakdown (NVS 2 – 4 NVO)

Columns: Metric · NVS · NVO
1. Valuation Multiples NVO
Forward P/E 16.2x 12.2x
Trailing P/E 30.6x 10.3x
PEG Ratio 3.81x 4.21x
EV / Revenue 7.5x 3.8x
2. Growth & Scale NVO
Revenue Growth (YoY) +4.7% +5.6%
Earnings Growth (YoY) -68.8% -15.8%
TTM Revenue (USD) $40.5B $51.5B
Market Cap $302.9B $180.7B
3. Profitability & Quality NVO
Gross Margin 75.2% 83.3%
Operating Margin 34.0% 50.8%
Net Profit Margin 17.5% 33.9%
Return on Equity (ROE) 24.3% 58.4%
4. Balance Sheet & Cash Flow NVS
Cash Generation (TTM) $17.0B EBITDA $6.94B
Cash Flow Margin 42.0% EBITDA Mgn 13.5%
Net Cash / Leverage $19.71 Book/Sh · 24.3% ROE $13.9B Net Debt (0.62x D/E)
Dividend Yield 2.96% 4.42%
5. Options & Positioning NVO
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 16.9% (6th %ile) 32.5% (25th %ile)
Put/Call OI Skew Thin ADR Chain 0.81x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat NVS
OpEx & R&D Intensity 41.2% of Rev ($16.7B) 32.5% of Rev ($16.7B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - General Operator Global GLP-1 Diabetes & Obesity Biologics Leader

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NVS (3) vs NVO (7)
Institutional Metric NVS NVO Criterion Row Edge
Market Capitalization
Scale
$302.9B $180.7B Larger Scale NVS
Trailing P/E Ratio
Valuation
30.6x 10.3x Lower Multiple NVO
Forward P/E Ratio
Valuation
16.2x 12.2x Lower Multiple NVO
Revenue Growth (YoY)
Growth
+4.7% +5.6% Higher Growth NVO
Operating Margin (TTM)
Profitability
34.0% 50.8% Higher Margin NVO
Net Profit Margin
Profitability
17.5% 33.9% Higher Margin NVO
Return on Equity (ROE)
Capital Efficiency
24.3% 58.4% Higher ROE NVO
52-Week Range Position
Momentum
81% ($123–$170) 23% ($35–$64) Stronger Trend NVS
Beta / 30D Volatility
Risk Regime
0.31β · 27% Vol 0.50β · 32% Vol Lower Realized Risk NVS
Unified Institutional Score
Composite Signal
41.5 / 100 (SELL) 41.8 / 100 (SELL) Higher Composite NVO
Trailing 12M Revenue (USD)
Operating Scale
$40.5B $51.5B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.2% 83.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.81x PEG · 7.5x EV/Rev 4.21x PEG · 3.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17.0B EBITDA ($19.71 Book/Sh · 24.3% ROE) $6.94B ($13.9B Net Debt (0.62x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NVO +0.14 pp
NVS: +7.28% · NVO: +7.42%
3M Horizon NVS +13.31 pp
NVS: +4.56% · NVO: -8.75%
6M Horizon NVS +14.14 pp
NVS: +8.34% · NVO: -5.8%
1Y Horizon NVS +37.65 pp
NVS: +22.5% · NVO: -15.15%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs NVO. Trailing 12-month operating profitability (NVS 34.0% vs NVO 50.8%) and valuation multiples (NVS 16.2x vs NVO 12.2x Forward P/E) are benchmarked directly in Pillar 4 below.

NVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40.5B
Gross Margin75.2%
Op. Margin34.0%
ROE / Fwd P/E24.3% · 16.2x
NVO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$51.5B
Gross Margin83.3%
Op. Margin50.8%
ROE / Fwd P/E58.4% · 12.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 16.9%
IV Percentile 6th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NVO CONSOLIDATION
94d in phase · OBV ACCUMULATION
Current IV 32.5%
IV Percentile 25th %ile
Put/Call OI Skew 0.81x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact NVO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NVS Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($16.7B)
90D Engineering Disclosures 0 Published
NVO Moat Profile High-Margin Pricing Power Moat
Global GLP-1 Diabetes & Obesity Biologics Leader
Operates vertically integrated peptide fermentation and auto-injector supply chains serving global diabetes and weight-management markets.
OpEx & R&D Reinvestment 32.5% of Rev ($16.7B)
90D Engineering Disclosures 0 Published

Investor FAQ NVS vs NVO Key Questions & Quantitative Answers

As of Nov 16, 2026, Novo-Nordisk A/S (NVO) is the stronger overall head-to-head candidate over Novartis AG (NVS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas NVO carries 41.8/100 (SELL) at $41.71 (12.2x Forward P/E, 50.8% operating margin). Defensive Composite Rating Caution: Although NVO compares more favorably head-to-head, both NVS (41.5/100 SELL) and NVO (41.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

NVO leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with NVO at +5.6% YoY revenue growth and -15.8% YoY earnings growth on $51.5B TTM revenue (83.3% gross margin, 50.8% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $51.5B for NVO. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 32.5% of Rev ($16.7B) (0 disclosures) for NVO.

NVO screens cheaper on headline valuation multiples. NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas NVO trades at 12.2x Forward P/E, 10.3x Trailing P/E, 4.21x PEG, and 3.8x EV/Revenue (13.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus NVO (58.4% ROE) capital efficiency.

In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk). By comparison, NVO carries 32.5% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.50β · 32% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.